摘要
目的:观察中药复方肠胃清口服液逆转大肠癌长春新碱耐药的作用,初步探讨其逆转耐药的作用机制。方法:建立人大肠癌耐长春新碱(VCR)细胞株HCT8/V裸鼠皮下移植瘤模型,随机分为正常对照组、VCR组、肠胃清组、肠胃清高剂量+VCR组、肠胃清低剂量+VCR组。治疗结束后计算瘤体抑制率;高效液相色谱法检测瘤内VCR药物浓度;流式细胞技术检测瘤内细胞周期和凋亡改变。结果:肠胃清高低剂量联合VCR的瘤体抑制率为47.47%、69.62%,明显高于单用肠胃清或VCR组;对照组VCR的含量为0.1745μg/g瘤重,而肠胃清高剂量联合VCR组的浓度为12.2236μg/g瘤重,是对照组的70.05倍;与对照组比较,药物干预后,G1期细胞明显增加,S期细胞明显低于对照组,细胞凋亡率明显增加,以肠胃清联合VCR组作用最强。结论:肠胃清逆转大肠癌移植瘤对VCR的耐药与通过增加瘤体内药物浓度、诱导细胞凋亡有关。
Objective： To investigate the reversal effect of ＂Changweiqing Fluid＂ （CWQ） on muhidrug resistance in human colorectal cancer cell and its mechanisms. Methods： Establish xenograft model of the vincristine（VCR）-risistant human colorectal cancer cell line HCT-8/V in nude mice. Then the mice were randomly divided into five groups： control group （NS）, CWQ group, VCR group, lower dose CWQ ＋ VCR group and higher dose CWQ ＋ VCR group. After treatment, the inhibition rate of tumor in each group were calculated. Intracellular VCR concentration in HCT-8/V cells was detected by HPLC; the diversify of the cell cycle and apoptosis was detected by FCM. Results： The inhibition rates in lower dose CWQ ＋ VCR group and higher dose CWQ ＋ VCR group were 47.47% , 69.62% respectively, which were significantly higher than that of CWQ or VCR groups. The concentration of VCR in NS group was 0. 174 5 μg/g of tumor weight, and in higher dose CWQ ＋ VCR group the concentration was 12. 223 6 μg/g, as high as 70.05 times of the NS group. Compared with control group, after drug intervention, ceils in G1 phase increased markedly and ceils in S phase decreased significantly, and the rate of apoptosis increased significantly, with the biggest change in CWQ ＋ VCR group. Conclusion： The reversal of VCR resistance in human colorectal cancer by ＂Changweiqing＂ （CWQ） may be associated with its inereasing drug concentration in tumor and inducing cell apoptosis.
出处
《上海中医药大学学报》
CAS
2009年第2期59-63,共5页
Academic Journal of Shanghai University of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(30672683)
上海市教委科研基金资助项目(05CZ16)
关键词
肠胃清
大肠癌
多药耐药
长春新碱
皮下移植瘤
Changweiqing（CWQ）
coloreetal cancer
multidrug resistance（MDR）
vincristine （VCR）
HCT-8/V tumor xenograft model
